#Argentina #Buenos Aires #Prestige Biopharma #Biosidus #Tuznue

Prestige Biopharma and Biosidus Partnership for Tuznue®

In a significant development for cancer treatment accessibility, Prestige Biopharma, renowned for its innovations in biopharmaceuticals, has entered an exclusive licensing agreement with Biosidus. This collaboration focuses on the commercial launch of Tuznue® (trastuzumab), a biosimilar to the widely known Herceptin®, across key Latin American markets, including Argentina, Mexico, Bolivia, and Paraguay.

What is Tuznue®?

Tuznue® is specifically designed as a cost-effective alternative to Herceptin®, targeting HER2-positive breast and gastric cancers. With the European Commission granting marketing authorization in September 2024, Tuznue® represents a pivotal addition to Prestige Biopharma’s portfolio, enhancing their offerings in biosimilar therapeutics. The drug will be instrumental in addressing the needs of patients in regions where access to expensive treatments has been a barrier.

The Partnership Dynamics

Under this agreement, Biosidus will take on the responsibility of marketing and distributing Tuznue® in the specified Latin American regions. With over 40 years of experience in biotechnology and a strong foothold in biosimilar development, Biosidus is well-equipped to penetrate these markets effectively. Prestige Biopharma shall provide the drug substance from its state-of-the-art EU-GMP-certified facility, ensuring quality production aligned with global standards.

Biosidus will then manufacture the drug product at its Buenos Aires facility, managing local distribution while also overseeing export operations to neighboring markets including Mexico, Paraguay, and Bolivia. This strategic structure not only optimizes the supply chain but also leverages local expertise to ensure that Tuznue® reaches those who need it most.

Statements from Leadership

Lisa S. Park, CEO of Prestige Biopharma, emphasized the importance of this collaboration, stating, "With Biosidus' proven track record in the region, we believe this partnership will significantly enhance the value and accessibility of our biosimilar portfolio. Together, we can make critical treatments available to a wider audience."

On the other hand, Mariano Elizalde, CEO of Biosidus, remarked on the alignment of their goals, saying, "We are excited to partner with Prestige Biopharma. This agreement not only bolsters our biosimilar portfolio but also underscores our commitment to expanding the availability of high-quality biotechnological medicines. Together, we aim to provide patients and healthcare providers with more affordable treatment options."

The Market Landscape

The need for affordable cancer treatments in Latin America cannot be overstated. With the rise in cancer diagnoses, especially breast and gastric cancers, the demand for effective yet cost-efficient therapies is greater than ever. Tuznue® stands as a beacon of hope for many patients who would otherwise be unable to afford heralded treatments.

About the Companies

Prestige Biopharma

Founded in 2015 and based in Singapore, Prestige Biopharma is a forward-thinking biopharmaceutical company with a diverse and expanding pipeline. Their commitment to innovation is highlighted by their first-in-class drug, ulenistamab, which has received Orphan Drug Designation and Fast Track status from major regulatory bodies including the U.S. FDA.

Biosidus

An Argentine pioneer in biotechnology, Biosidus has carved out a leading position in the Latin American market over its 42-year history. The company's focus on developing, producing, and marketing high-quality biopharmaceuticals at affordable prices has enabled it to gain traction in emerging markets beyond Latin America, including parts of Asia, Africa, and Eastern Europe.

By leveraging their expertise and resources, both companies are poised to make a significant impact on cancer treatment accessibility across Latin America. Their collaboration represents a critical step forward, showcasing how strategic partnerships in the biopharmaceutical sector can lead to improved healthcare outcomes for patients in need.